Advances in treating chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affects mostly elderly CLL patients, and is incurable without allogeneic transplantation. Although classic chemo(immuno)therapy is still the standard of care for patients in need of treatment, this paradigm might change in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tausch, Eugen, Mertens, Daniel, Stilgenbauer, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculty of 1000 Ltd 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126532/
https://www.ncbi.nlm.nih.gov/pubmed/25165564
http://dx.doi.org/10.12703/P6-65
_version_ 1782329924971921408
author Tausch, Eugen
Mertens, Daniel
Stilgenbauer, Stephan
author_facet Tausch, Eugen
Mertens, Daniel
Stilgenbauer, Stephan
author_sort Tausch, Eugen
collection PubMed
description Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affects mostly elderly CLL patients, and is incurable without allogeneic transplantation. Although classic chemo(immuno)therapy is still the standard of care for patients in need of treatment, this paradigm might change in the near future with the advent of new therapeutic agents targeting major pathogenic pathways in CLL.
format Online
Article
Text
id pubmed-4126532
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Faculty of 1000 Ltd
record_format MEDLINE/PubMed
spelling pubmed-41265322014-08-27 Advances in treating chronic lymphocytic leukemia Tausch, Eugen Mertens, Daniel Stilgenbauer, Stephan F1000Prime Rep Review Article Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affects mostly elderly CLL patients, and is incurable without allogeneic transplantation. Although classic chemo(immuno)therapy is still the standard of care for patients in need of treatment, this paradigm might change in the near future with the advent of new therapeutic agents targeting major pathogenic pathways in CLL. Faculty of 1000 Ltd 2014-08-01 /pmc/articles/PMC4126532/ /pubmed/25165564 http://dx.doi.org/10.12703/P6-65 Text en © 2014 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Tausch, Eugen
Mertens, Daniel
Stilgenbauer, Stephan
Advances in treating chronic lymphocytic leukemia
title Advances in treating chronic lymphocytic leukemia
title_full Advances in treating chronic lymphocytic leukemia
title_fullStr Advances in treating chronic lymphocytic leukemia
title_full_unstemmed Advances in treating chronic lymphocytic leukemia
title_short Advances in treating chronic lymphocytic leukemia
title_sort advances in treating chronic lymphocytic leukemia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126532/
https://www.ncbi.nlm.nih.gov/pubmed/25165564
http://dx.doi.org/10.12703/P6-65
work_keys_str_mv AT tauscheugen advancesintreatingchroniclymphocyticleukemia
AT mertensdaniel advancesintreatingchroniclymphocyticleukemia
AT stilgenbauerstephan advancesintreatingchroniclymphocyticleukemia

Ejemplares similares